Aristotle Capital Boston’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.6M | Sell |
|
|||||
|
2025
Q1 | $15.7M | Sell |
|
|||||
|
2024
Q4 | $24M | Sell |
|
|||||
|
2024
Q3 | $28.5M | Sell |
|
|||||
|
2024
Q2 | $31.1M | Buy |
|
|||||
|
2024
Q1 | $40.3M | Sell |
|
|||||
|
2023
Q4 | $36.3M | Sell |
|
|||||
|
2023
Q3 | $31.1M | Sell |
|
|||||
|
2023
Q2 | $33.7M | Buy |
|
|||||
|
2023
Q1 | $31.6M | Buy |
|
|||||
|
2022
Q4 | $33.5M | Sell |
|
|||||
|
2022
Q3 | $31.1M | Sell |
|
|||||
|
2022
Q2 | $37.2M | Buy |
|
|||||
|
2022
Q1 | $49.1M | Sell |
|
|||||
|
2021
Q4 | $66.2M | Sell |
|
|||||
|
2021
Q3 | $91.9M | Sell |
|
|||||
|
2021
Q2 | $109M | Sell |
|
|||||
|
2021
Q1 | $94.4M | Sell |
|
|||||
|
2020
Q4 | $88.9M | Sell |
|
|||||
|
2020
Q3 | $91.8M | Buy |
|
|||||
|
2020
Q2 | $68.9M | Buy |
|
|||||
|
2020
Q1 | $45.4M | Sell |
|
|||||
|
2019
Q4 | $57.5M | Buy |
|
|||||
|
2019
Q3 | $48.7M | Buy |
|
|||||
|
2019
Q2 | $51.2M | Buy |
|
|||||
|
2019
Q1 | $50.6M | Buy |
|
|||||
|
2018
Q4 | $16.3M | Buy |
|
|||||
|
2018
Q3 | $16.9M | Buy |
|
|||||
|
2018
Q2 | $13.5M | Sell |
|
|||||
|
2018
Q1 | $26.2M | Buy |
|
|||||
|
2017
Q4 | $15.6M | Buy |
|
|||||
|
2017
Q3 | $11.9M | Buy |
|
|||||
|
2017
Q2 | $8.71M | Buy |
|
|||||
|
2017
Q1 | $6.02M | Buy |
|
|||||
|
2016
Q4 | $4.93M | Buy |
|
|||||
|
2016
Q3 | $4.3M | Buy |
|
|||||
|
2016
Q2 | $4.04M | Buy |
|
|||||
|
2016
Q1 | $3.66M | Buy |
|
|||||
|
2015
Q4 | $3.62M | Buy |
|
|||||
|
2015
Q3 | $2.44M | Buy |
|
|||||
|
2015
Q2 | $2.64M | Buy |
|
|||||
|
2015
Q1 | $2.14M | Buy |
|
|||||
|
2014
Q4 | $1.07M | Buy |
|